LL-37 suppresses sodium nitroprusside-induced apoptosis of systemic sclerosis dermal fibroblasts

Experimental Dermatology

Volumn 20, Issue 10, 2011, Pages 843-845

  Kim, Hee Jung ^a   Cho, Dae Ho ^b   Lee, Kyung Jin ^a   Cho, Chul Soo ^a   Bang, Sa Ik ^c   Cho, Baik Kee ^a   Park, Hyun Jeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Antimicrobial peptide; Apoptosis; Human dermal fibroblasts; LL 37; Systemic sclerosis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CASPASE 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NITROPRUSSIDE SODIUM; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ENZYME ACTIVATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

ANTIMICROBIAL CATIONIC PEPTIDES; APOPTOSIS; CASE-CONTROL STUDIES; CASPASE 3; CYCLOOXYGENASE 2; FIBROBLASTS; HUMANS; MAP KINASE SIGNALING SYSTEM; NITROPRUSSIDE; SCLERODERMA, SYSTEMIC;

EID: 80052968673     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2011.01327.x     Document Type: Letter

References (27)

1. Rodnan G P, Lipinski E, Luksick J. Arthritis Rheum 1979: 22: 130-140.
2. Black C M, Stephen C. Systemic sclerosis (scleroderma) and related disorders. In: Maddison P J, Isenberg D A, Woo P, Glass D N, eds. Oxford Textbook of Rheumatology. Oxford: Oxford University Press, 1993: 771-789.
3. Medsger T A J. Systemic sclerosis (scleroderma), clinical aspects. In: Koopman W J, ed. Arthritis and Allied Conditions, 13th edn. Baltimore: Williams and Wilkins, 1997: 1433-1464.
4. Hesselstrand R, Scheja A, Akesson A. Ann Rheum Dis 1998: 57: 682-686.
5. Santiago B, Galindo M, Rivero M et al. Arthritis Rheum 2001: 44: 1667-1676.
6. Jelaska A, Korn J H. Arthritis Rheum 2000: 43: 2230-2239.
7. Di Nardo A, Vitiello A, Gallo R L. J Immunol 2003: 170: 2274-2278.
8. Braff M H, Zaiou M, Fierer J et al. Infect Immun 2005: 73: 6771-6781.
9. Murakami M, Ohtake T, Dorschner R A et al. J Invest Dermatol 2002: 119: 1090-1095.
10. Dorschner R A, Pestonjamasp V K, Tamakuwala S et al. J Invest Dermatol 2001: 117: 91-97.
11. Zasloff M. Nature 2002: 415: 389-395.
12. Nagaoka I, Tamura H, Hirata M. J Immunol 2006: 176: 3044-3052.
13. Aarbiou J, Tjabringa G S, Verhoosel R M et al. Inflamm Res 2006: 55: 119-127.
14. Park H J, Ock S M, Kim H J et al. Exp Dermatol 2010: 19: e258-e264.
15. Howell M D, Gallo R L, Boguniewicz M et al. Immunity 2006: 24: 341-348.
16. Yamasaki K, Di Nardo A, Bardan A et al. Nat Med 2007: 13: 975-980.
17. Tovar-Castillo L E, Cancino-Diaz J C, Garcia-Vazquez F et al. Int J Dermatol 2007: 46: 239-246.
18. Barlow P G, Li Y, Wilkinson T S et al. J Leukoc Biol 2006: 80: 509-520.
19. Chamorro C I, Weber G, Gronberg A et al. J Invest Dermatol 2009: 129: 937-944.
20. Okumura K, Itoh A, Isogai E et al. Cancer Lett 2004: 212: 185-194.
21. Kroemer G, Reed J C. Nat Med 2000: 6: 513-519.
22. Philchenkov A, Zavelevich M, Kroczak T J et al. Exp Oncol 2004: 26: 82-97.
23. Anderson W F, Umar A, Viner J L et al. Curr Pharm Des 2002: 8: 1035-1062.
24. Liou J Y, Ellent D P, Lee S et al. Stem Cells 2007: 25: 1096-1103.
25. Funayama E, Chodon T, Oyama A et al. J Invest Dermatol 2003: 121: 1326-1331.
26. Kim J Y, Kwok S K, Hur K H et al. Clin Exp Immunol 2008: 152: 328-335.
27. Pugazhenthi S, Nesterova A, Sable C et al. J Biol Chem 2000: 275: 10761-10766.